Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionValeo Financial Advisors, LLC
Latest Disclosed Ownership3,500 shares
Latest Disclosed Value $ 1,562,895
Valeo Financial Advisors, LLC ownership in VRTX / Vertex Pharmaceuticals Incorporated

On May 8, 2026 - Valeo Financial Advisors, LLC filed a 13F-HR form disclosing ownership of 3,500 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $1,562,890 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 4, 2026 disclosing 4,682 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -25.25% during the quarter. The current value of the position is $1,563,905 USD.

Valeo Financial Advisors, LLC has a history of taking positions in derivatives of the underlying security (VRTX) in the form of stock options.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

VRTX / Vertex Pharmaceuticals Incorporated Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-08 2026-03-31 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 3,500 -1,182 -25.25 1,563 -26.39 0.0373
2026-02-04 2025-12-31 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 4,682 -74 -1.56 2,123 13.96 0.0471
2025-11-03 2025-09-30 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 4,756 185 4.05 1,863 -8.50 0.0424
2025-09-12 2025-06-30 13F/A-1 VERTEX PHARMACEUTICALS IN Stock 92532F100 4,571 -167 -3.52 2,035 -11.41 0.0500
2025-07-22 2025-06-30 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 4,571 -167 2,035 0.0490
2025-04-30 2025-03-31 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 4,738 -1,435 -23.25 2,297 -7.57 0.0640
2025-01-30 2024-12-31 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 6,173 -252 -3.92 2,486 -16.83 0.0692
2024-10-10 2024-09-30 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 6,425 540 9.18 2,988 8.34 0.0852
2024-07-10 2024-06-30 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 5,885 -453 -7.15 2,759 8.50 0.0862
2024-04-25 2024-03-31 13F/A-1 VERTEX PHARMACEUTICALS IN Stock 92532F100 6,338 735 13.12 2,542 11.54 0.0911
2024-04-19 2024-03-31 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 6,747 1,144 2,820 0.0970
2024-01-29 2023-12-31 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 5,603 1,256 28.89 2,280 50.83 0.0921
2023-10-20 2023-09-30 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 4,347 36 0.84 1,512 -0.40 0.0689
2023-07-14 2023-06-30 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 4,311 -1,031 -19.30 1,517 -9.86 0.0693
2023-04-17 2023-03-31 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 5,342 662 14.15 1,683 24.57 0.0811
2023-02-09 2022-12-31 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 4,680 -590 -11.20 1,351 -11.47 0.0741
2022-10-31 2022-09-30 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 5,270 1,009 23.68 1,526 27.06 0.0973
2022-08-03 2022-06-30 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 4,261 956 28.93 1,201 39.17 0.0754
2022-04-28 2022-03-31 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 3,305 1,080 48.54 863 76.48 0.0439
2022-01-07 2021-12-31 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 2,225 2,225 489 0.0265
2021-07-22 2021-06-30 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 0 -5,197 -100.00 0 -100.00
2021-04-12 2021-03-31 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 5,197 195 3.90 1,117 -5.50 0.0517
2021-02-11 2020-12-31 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 5,002 4,590 1,114.08 1,182 955.36 0.0608
2020-10-28 2020-09-30 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 412 -411 -49.94 112 -53.14 0.0098
2020-07-20 2020-06-30 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 823 135 19.62 239 40.59 0.0218
2020-04-13 2020-03-31 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 688 -689 -50.04 170 -43.52 0.0181
2020-01-24 2019-12-31 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 1,377 401 41.09 301 82.42 0.0292
2019-10-15 2019-09-30 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 976 -93 -8.70 165 -15.82 0.0182
2019-07-10 2019-06-30 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 1,069 417 63.96 196 63.33 0.0224
2019-04-12 2019-03-31 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 652 -29 -4.26 120 6.19 0.0146
2019-01-30 2018-12-31 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 681 105 18.23 113 15.31 0.0158
2018-11-01 2018-09-30 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 576 247 75.08 98 68.97 0.0132
2018-08-14 2018-06-30 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 329 -292 -47.02 58 -42.57 0.0081
2018-04-12 2018-03-31 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 621 321 107.00 101 124.44 0.0162
2018-02-09 2017-12-31 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 300 100 50.00 45 50.00 0.0074
2017-11-15 2017-09-30 13F/A-1 VERTEX PHARMACEUTICALS INC COM Stock 92532F100 200 200 30 0.0068
2017-11-14 2017-09-30 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 200 30
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2025-04-30 2025-03-31 13F VERTEX PHARMACEUTICALS IN Stock Put 0 -100.00 0 -100.00 n/a n/a n/a
2025-01-30 2024-12-31 13F VERTEX PHARMACEUTICALS IN Stock Put 1,100 443 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.